Bimagrumab and Apitegromab: Muscle-Preserving Antibodies
Bimagrumab (Lilly) and apitegromab (Scholar Rock, ISEMBYLD) are IV monoclonal antibodies, not peptides. What the BELIEVE, EMBRAZE and SAPPHIRE trials showed about fat, lean mass and safety.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Track your peptide protocols in PeptIQ
Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.
Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
The Short Answer
Weight loss on GLP-1 drugs includes some lean mass as well as fat. Two drugs that target the myostatin/activin pathway, a natural brake on muscle growth, are being tested to change that ratio:
Bimagrumab (Eli Lilly) blocks activin type II receptors (ActRIIA and ActRIIB). It is investigational and not approved anywhere we found.
Apitegromab (Scholar Rock) binds the inactive precursor forms of myostatin so it can't be activated. It is FDA-approved as ISEMBYLD, but only for spinal muscular atrophy (SMA). Its obesity use is still investigational.
Neither is a peptide. Both are fully human monoclonal antibodies, large proteins made in cell culture and given by intravenous (IV) infusion in trials. They can't be compounded and aren't "research peptides." Claims of "muscle gain in a pill" for either drug are wrong. Neither has been studied as a pill, and the goal in the obesity trials was preserving lean mass during weight loss, not building muscle.
This page summarizes published and sponsor-reported trial data. It isn't dosing guidance.
Why the Myostatin Pathway
Myostatin and activin A signal through activin type II receptors to limit muscle growth. Blocking that pathway increases muscle mass in animals and people. The obesity question is whether blocking it during GLP-1 weight loss can tilt losses toward fat.
PeptIQ has covered this pathway in the research wiki, including a 2022 review of myostatin-inhibiting strategies. Peptide-based ideas such as follistatin-344 and ACE-031 have much weaker human evidence than the two antibodies here. Our follistatin 344 guide walks through the gene-therapy trials, the randomized ACE-083 results and what laboratory testing found in black-market vials, and our ACE-031 guide covers the receptor-trap version whose trials were stopped over a blood-vessel signal.
Bimagrumab: What the Trials Show
BELIEVE: bimagrumab with semaglutide (Nature Medicine, March 2026)
BELIEVE (NCT05616013) was a Lilly-funded, placebo-controlled phase 2 trial. Bimagrumab was double-blind; semaglutide was given open-label.
507 adults with obesity (BMI ≥30, or ≥27 with a weight-related condition), without diabetes.
Nine groups for 48 weeks: placebo, bimagrumab alone (two IV doses), semaglutide alone (two doses) and four combinations. An open-label extension ran to week 72.
Primary endpoint: change in body weight at week 48.
Weight, week 48 (least-squares mean):
Group
Body weight change (range across doses)
% change (range across doses)
Placebo
-3.3 kg
-3.5%
Bimagrumab alone (two doses)
-6.0 to -9.3 kg
-5.6% to -8.6%
Semaglutide alone (two doses)
-9.8 to -14.2 kg
-9.8% to -13.5%
Combinations (four groups)
-12.7 to -17.8 kg
-12.0% to -16.4%
The largest losses in each row came from high-dose bimagrumab (-9.3 kg), semaglutide 2.4 mg (-14.2 kg) and the high-dose combination (-17.8 kg).
The high-dose combination lost more weight than semaglutide 2.4 mg alone (P < 0.05).
Body composition, week 48 (DXA scan):
Total lean mass changed by +1.0% to +1.1% with bimagrumab alone, -4.7% to -6.9% with semaglutide alone, and -0.8% to -2.3% with the combinations, versus -0.9% with placebo.
Share of weight lost that was fat ("fat loss index"): 100% with high-dose bimagrumab alone, 71.1% with semaglutide 2.4 mg, and 92.3% with the high-dose combination.
Visceral fat fell 41.0% to 54.8% with the combinations.
At week 72 the pattern held: fat accounted for 92.2% of weight lost with the high-dose combination versus 75.6% with semaglutide 2.4 mg.
Safety and tolerability:
Common adverse events with bimagrumab were muscle spasms (mostly cramps), diarrhea and acne. Semaglutide brought its usual nausea, diarrhea, constipation and fatigue.
Discontinuations due to adverse events were 14.0% to 21.4% in the bimagrumab-alone groups, versus 3.6% to 8.8% with semaglutide, 5.3% to 12.5% with the combinations, and 3.6% with placebo.
Earlier: bimagrumab in type 2 diabetes (JAMA Network Open, 2021)
A 48-week phase 2 trial randomized 75 adults with type 2 diabetes and overweight or obesity to IV bimagrumab or placebo. Bimagrumab changed fat mass by -20.5% versus -0.5%, lean mass by +3.6% versus -0.8%, and HbA1c by -0.76 points versus -0.04. Only participants who completed treatment were analysed, and 58 of 75 finished.
A 2026 meta-analysis of four randomized trials (268 participants) found bimagrumab reduced weight and fat and increased lean mass versus placebo. It also linked bimagrumab to higher LDL cholesterol, more discontinuations, muscle spasms and diarrhea.
What's next for bimagrumab
ClinicalTrials.gov lists a Lilly phase 2 of bimagrumab with tirzepatide (NCT06643728, active, not recruiting), an academic phase 2 at Massachusetts General Hospital (NCT05933499), and a new Lilly phase 2 in heart failure with preserved ejection fraction (NCT07920887, not yet recruiting). We found no registered phase 3 in obesity.
Apitegromab: What the Trials Show
Approved use: spinal muscular atrophy
FDA approved apitegromab as ISEMBYLD (BLA 761463) for SMA in patients 2 years and older who are already receiving an SMN2-targeted treatment (nusinersen or risdiplam, for example). The label lists initial US approval in 2026. DailyMed shows a September 2026 label.
The approval rests on SAPPHIRE (NCT05156320), a phase 3 trial of 188 nonambulatory patients aged 2 to 21, published in Lancet Neurology (2025). In the main 2–12-year-old group, motor function on the HFMSE scale improved by 1.8 points more than placebo for both doses combined (p = 0.019). The higher dose alone did not reach statistical significance versus placebo (1.4 points, p = 0.11). The FDA label reports its own analysis for the approved (lower) dose, a 2.2-point improvement versus placebo (p = 0.01), and calls it "nominally" statistically significant. The label notes the higher dose did not show additional efficacy.
Label warning: ISEMBYLD may increase the risk of fractures, including serious femur fractures. In SAPPHIRE, 9% of patients on the approved dose had a fracture, versus 2% on placebo. The most common adverse reactions included upper respiratory infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis and hypersensitivity.
This is a medicine for a serious neuromuscular disease. The SMA approval does not cover obesity or general muscle building.
Obesity: EMBRAZE with tirzepatide (Nature Medicine, 2026)
EMBRAZE (NCT06445075) was a phase 2 proof-of-concept trial that enrolled 102 adults with overweight or obesity and without diabetes. Everyone took tirzepatide for 24 weeks and was randomized to IV apitegromab or placebo. The primary endpoint was change in lean mass by DXA.
The peer-reviewed results (Pratley et al., Nature Medicine, 2026) report:
At week 24, participants on apitegromab lost 1.9 kg less lean mass than those on placebo (P = 0.001), despite similar total weight loss. The authors describe this as 54.9% retention of lean mass relative to placebo.
Adverse events occurred in 76% of the apitegromab group and 71% of the placebo group. Serious adverse events occurred in one participant in each arm (2%).
Scholar Rock's June 2025 topline also reported total weight loss of 12.3% with the combination versus 13.4% with tirzepatide alone, and a fat/lean split of 85%/15% versus 70%/30%. This was a 24-week proof-of-concept trial. Scholar Rock's current public pipeline doesn't name a follow-on obesity trial.
Don't rank them against each other. The trials differ in GLP-1 partner, duration, size and endpoints. Two other cautions:
"Lean mass" on DXA isn't the same as muscle strength. It also includes water and organs. Function outcomes matter and are less well reported.
Combination therapy didn't always add weight loss. In EMBRAZE, total weight loss was similar with or without apitegromab. The benefit is in what was lost.
If you're on a GLP-1, PeptIQ lets you log weight, waist, workouts and body-composition scans next to your doses. That way you and your clinician can see whether the scale is moving because of fat or lean mass.
Frequently Asked Questions
Q: Are bimagrumab and apitegromab peptides?
A: No. Both are fully human monoclonal antibodies given by IV infusion in trials. They are much larger than peptides and can't be compounded.
Q: Is bimagrumab FDA approved?
A: No. It is investigational. Its largest obesity trial, BELIEVE, is a published phase 2.
Q: Is apitegromab approved?
A: Yes, as ISEMBYLD, for spinal muscular atrophy in patients 2 and older already on an SMN2-targeted therapy. It is not approved for obesity.
Q: Does bimagrumab plus semaglutide build muscle?
A: In BELIEVE, lean mass fell only 0.8% to 2.3% with the combinations versus 4.7% to 6.9% with semaglutide alone, while fat loss increased. That is preservation, not muscle gain.
Q: Is there a pill version of these drugs?
A: No. Both trials used IV infusions of the antibody. Semaglutide and tirzepatide in those trials were weekly injections.
Q: What are the main side effects?
A: For bimagrumab: muscle spasms, diarrhea and acne. For apitegromab in SMA: a label warning for fractures, plus infections, vomiting, cough and headache.
This article is educational content from PeptIQ. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.